Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Archived or fresh tumor biopsy samples will be collected.

Tumor biopsy

GSK Clinical Trials

This is a single arm interventional molecular analysis study with no administration of investigational product and no masking. This multicenter study will involve participants with advanced/metastatic disease for the purpose of collecting tumor tissue and blood samples for broad molecular analysis and examining the expression of specific biomarkers using validated clinical assays.

Molecular Disease Characterization Initiative (MDCI)

A Global, Molecular Disease Characterization Initiative (MDCI) in Oncology Clinical Trials

IPD for this study will be made available via the Clinical Study Data Request site.

Blood samples were collected for clinical biomarker testing and a tumor specimen was collected as per tumor specimen collection requirements. The specimen was evaluated by immunohistochemistry (IHC) to determine the expression of tumor specific antigens and immune markers. The ICOS is the biomarkers and data for participants with its positive status has been presented.

Blood samples were collected for clinical biomarker testing and a tumor specimen was collected as per tumor specimen collection requirements. The specimen was evaluated by immunohistochemistry (IHC) to determine the expression of tumor specific antigens and immune markers. The NY-ESO-1 and LAGE-1a are biomarker and data for number of participants with its positive status has been presented.

Blood samples were collected for clinical biomarker testing and a tumor specimen was collected as per tumor specimen collection requirements. The specimen was evaluated by immunohistochemistry (IHC) to determine the expression of tumor specific antigens and immune markers. The PD-L1 is a biomarker and data for number of participants with its positive status has been presented.

GlaxoSmithKline

Enrolled population included all participants who signed the informed consent form (ICF) and met inclusion criteria

Participants with advanced/metastatic diagnosis of malignancy disease underwent tumor biopsy.

Participants Who Underwent Tumor Biopsy

Age, Continuous

Sex: Female, Male

White

Race/Ethnicity, Customized

GSK Response Center

Enrolled population included all participants who signed the informed consent form (ICF) and met inclusion criteria.

Spots Global Cancer Trial Database for Molecular Disease Characterization Initiative (MDCI)

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial